Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03252223 · ClinicalTrials.gov registry record · Phase 4
Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT03252223 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 33 participants.
The verdict
NCT03252223, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Women with PCOS suffer from anovulation and, as a result, infertility. Efforts to clinically induce ovulation in these women using follicle stimulating hormone (FSH) administered subcutaneously seemingly requires prolonged administration compared to that of ovulatory women without PCOS. The apparent differing ovarian responsiveness to FSH between PCOS and normal women has not been carefully studied. We propose to address this issue by performing a dose-response study and examine ovarian follicle (estrogen, E2) responses to FSH administered subcutaneously in women with PCOS compared to responses observed in normal women.
Interventions
- DRUG Recombinant Follicle Stimulating Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03252223
The ClinicalTrials.gov registry entry for NCT03252223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Follicle Stimulating Hormone is the first listed.
NCT03252223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03252223 about?
NCT03252223 is a clinical study titled "Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS". Women with PCOS suffer from anovulation and, as a result, infertility. Efforts to clinically induce ovulation in these women using follicle stimulating hormone (FSH) administered subcutaneously seemingly requires prolonged administration compared to that of ovulatory women without PCOS. The apparent...
What is the current status of trial NCT03252223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2017-10-02. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03252223?
The interventions under investigation include: Recombinant Follicle Stimulating Hormone (DRUG).
Who is sponsoring clinical trial NCT03252223?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.